Dermira Inc. priced its offering of 9,811,321 common shares at $13.25 per share.
The Menlo Park, Calif.-based company also granted underwriters a 30-day option to buy up to an additional 1,471,698 shares at the same price.
Dermira expects gross proceeds of about $130 million from the offering.
Citigroup, Cowen, Cantor Fitzgerald & Co. and Guggenheim Securities are acting as book runners for the offering, while Needham & Co. and H.C. Wainwright & Co. are acting as co-managers.
Dermira develops and commercializes therapies for patients with skin conditions.